Cryoablation for Atrial Fibrillation Using POLARx

This study is a multi-centre research report that evaluates the safety, efficacy, and feasibility of same-day discharge for cryoballoon pulmonary vein isolation (PVI) using POLARx compared to Arctic Front Advance. The study involved 1,688 patients, with equal numbers undergoing PVI with both devices. The findings indicate that contemporary cryoablation is a safe and effective method for achieving PVI in patients with atrial fibrillation, demonstrating a procedural success rate exceeding 99% and a major complication rate of less than 1%. Notably, POLARx achieved temperatures approximately 10°C lower than those reported with Arctic Front Advance, with the time to reach a nadir temperature of −40°C being a predictive factor for successful PVI. The report concludes that while POLARx shows similar safety and efficacy to Arctic Front Advance, it necessitates modified cryoablation targets, warranting further prospective testing and outcome studies to optimize its use.